NIH Awards Startup Cellular Research $360K to Develop Array-based Noninvasive Prenatal T21 Test | GenomeWeb

Cellular Research, a Bay Area company established a year ago by the cofounders of Affymetrix and Fluidigm, has received federal funding to develop a non-invasive test for detecting Down syndrome in prenatal samples using a new array-based DNA molecule counting approach.

According to the abstract of the $360,000 National Institutes of Health grant, Cellular Research aims to develop a "faster and cheaper single-molecule counting system" that will rival a non-invasive massively parallel sequencing test to detect trisomy 21 in fetal DNA present in maternal plasma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.